Open All

Pantoprazole

Proton pump inhibitor

CCP: Erosive esophagitis, short term treatment of GERD, Zollinger-Ellison syndrome, peptic ulcer disease

 

  • Hypersensitivity
  • Concomitant use with rilpivirine.

Caution

  • Long term use
  • High dose
  • Hypomagnesemia
  • Patients 50 years and older.
  • Concomitant use with Clopidogrel.

CCP: All indications

  • 40-80 mg IV
  • 8 mg/hr IV infusion

CCP: All indications

  • 15-24 kg
    • 20- 40 mg IV
  • 24-34 kg
    • 40-60 mg IV
  • > 35 kg
    • 60-80 mg IV

Not supplied by BCEHS

  • 40 mg/vial
  • 20 mg tablet
  • 40 mg tablet

Inhibits gastric parietal cell hydrogen-potassium ATPase. This results in the blocking of acid secretion in the stomach.

Onset: PO 2.5 hours, IV 15-30 minutes

Duration: 7 days

Peak plasma time: 2.8 hours.

Half-life: 1 hour

  • Headache
  • Abdominal pain
  • Facial edema
  • Generalized edma
  • Chest pain
  • Diarrhea
  • Constipation
  • Pruritus
  • Rash
  • Hyperglycemia
  • Nausea and vomiting
  • PPI’s are possibly associated with increased incidence of CDAD.
  • Cutaneous lupus erythematosus and systemic lupus erythematosus reported with PPI’s.
  • Caution with severe hepatic impairment.
  • PPI’s may be associated with an increased risk of osteoporosis related fractures.
  • PPI’s may decrease the effectiveness of Plavix.
  • Hypomagnesemia may occur with prolonged use.
  • Therapy increases risk of Salmonella, Campylobacter, and other infections.
  • Infusion thrombophlebitis
  • Acute interstitial nephritis
  • Acute tubulointerstitial nephritis
  • Increased risk of fundic gland polyps.
  • May elevate or prolong serum methotrexate.
  • Nelfinavir
  • Rilpivirine
  • Acalabrutinib
  • Atazanavir
  • Bosutinib
  • Captopril
  • Cefditoren pivoxil
  • Cefpodoxime proxetil
  • Cefuroxime axetil
  • Dacomitinib
  • Dasatinib
  • Dextroamphetamine
  • Erlotinib
  • Ferrous gluconate
  • Ferrous sulfate
  • Fosinipril
  • Gefitinib
  • Ketoconazole
  • Levothyroxine
  • Mefenamic acid
  • Mesalamine
  • Methylphenidate
  • Neratinib
  • Nilotinib
  • Pazopanib
  • Pexidartinib
  • Posaconazole
  • Selpercatinib
  • Triazolam
  • Velpatasvir

Are you sure you want to sign out?

Sign Out Cancel

loading